TNYA

Tenaya Therapeutics, Inc. (TNYA) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.1 (Weak)

TNYA appears to rely on product differentiation and clinical know-how rather than protected brands or proprietary standards, so peers can more easily match its value proposition over time.

No evidence of broad regulatory exclusivity or entrenched intellectual-property barriers is provided here, which limits durable pricing power versus larger semiconductor peers with deeper patent portfolios.

The company’s negative TTM ROIC and ROCE suggest its current asset base is not yet converting into durable economic returns, which weakens proof of intangible-led advantage versus peers.

Compared with established analog and mixed-signal peers, TNYA’s intangible assets look narrower and less monetizable, so they are less likely to sustain margins through a full cycle.

Switching Costs

Score:

TNYA does not appear to have deeply embedded system-level integration that would make customer replacement costly, so retention is likely more price- and performance-sensitive than for incumbent peers.

The very high cash conversion cycle indicates working-capital intensity rather than customer lock-in, which suggests limited evidence of contractual or technical switching friction.

In semiconductor markets, switching costs are strongest when designs are qualified into long-life platforms, but no such peer-level lock-in is evidenced here for TNYA.

Relative to peers with broad installed bases and long qualification cycles, TNYA’s switching costs appear materially weaker and therefore less supportive of durable margins.

Network Effects

Score:

TNYA does not operate a platform or marketplace where more users directly increase value for other users, so classic network effects are not evident.

Its products do not appear to benefit from self-reinforcing ecosystem adoption at the level seen in dominant software or semiconductor platform peers.

Without a visible developer, data, or user network that compounds over time, peer comparison remains unfavorable on this moat dimension.

As a result, network effects contribute little to long-term pricing power or retention versus peers.

Cost Advantage

Score:

TNYA’s negative ROIC and ROCE indicate that current operating economics are not yet translating into a cost position that beats peers on a durable basis.

The low asset turnover suggests the company is not extracting superior revenue from its asset base, which weakens evidence of scale-driven unit-cost advantage.

Compared with larger peers that can spread R&D, manufacturing, and support costs across higher volumes, TNYA appears structurally disadvantaged on cost absorption.

No evidence is provided that TNYA can sustainably underprice peers while preserving margins, so cost advantage looks limited.

Efficient Scale

Score:

TNYA does not appear to serve a naturally limited niche with enough scale to deter entry, so efficient-scale protection is not clearly present.

The semiconductor market is competitive and populated by larger incumbents, which makes it harder for TNYA to enjoy a protected local or category monopoly.

Compared with peers that have entrenched customer bases and high fixed-cost leverage, TNYA’s scale does not yet look sufficient to create a durable barrier to entry.

The company’s current efficiency metrics do not show the kind of operating leverage that would make its scale self-reinforcing versus peers.

Overall Score

Score:

TNYA’s moat appears weak versus peers because none of the five structural drivers show durable evidence of pricing power, retention, or scale-based protection, and the provided profitability and efficiency metrics reinforce that the business is not yet converting operations into lasting competitive advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Tenaya Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →